Morphogenesis, Inc.

Development of platform technology for the isolation, growth and maintenance of adult stem cells

Morphogenesis is a privately held cell therapy company developing platforms to generate novel products for the cell therapy and tissue engineering markets. Dr. Patricia and Michael Lawman co-founded Morphogenesis in 1995.

Pat Lawman, Dr., CEO
Michael Lawman, Dr., President and Chairman of the Board
Morris Behar, COO

Patricia D. Lawman, PhD
Michael JP Lawman, PhD
Morris Behar
David P.A. Lawman
Grahame Cook

Patricia D. Lawman, PhD
Michael J.P. Lawman, PhD
Beverly Koller, PhD
Michael D.P. Boyle, PhD
Gwenn-aël Danet-Desnoyers, PhD
Adrian P. Gee, PhD

209 State Street
Oldsmar, FL 34677
USA
Phone: +1-813-855-9844
Fax: +1-813-854-2340

Morphogenesis has developed three platforms; cell therapy, immunotherapy and supporting technologies. Morphogenesis’ principle technology, MATCH™, resolves tissue shortage and graft rejection issues. MATCH technology helps to identify MHC (Major Histocompatibility complex) mismatches between donor and recipient. This platform includes the identification of stem cells (MG-1™) antigen and monoclonal antibodies), stem cell separation (PACS™) and stem cell expansion/growth factors.

The Polymer-Antibody Cell Separation (PACS™) system combines patented cell-specific antibodies with a special polymer that has no affinity for the stem cells themselves, thus preventing unwanted cell collection.

The company’s ImmuneFx™ is a cancer vaccine utilising bacterial antigens to induce a strong immune response of the patient’s immune system directed specifically to the tumour.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.